Navigation Links
TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

SAN DIEGO, May 26 /PRNewswire/ -- TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that Phase 1 clinical results from studies of TRC105 and TRC102 in patients with advanced cancer will be presented at the American Society of Clinical Oncology annual meeting this May 28th and 29th in Orlando, Florida. Both programs target unique pathways with the potential for broad application to a wide variety of cancer types.

TRC105 is a monoclonal antibody that binds CD105 (endoglin), a membrane receptor on endothelial cells that is required for angiogenesis. By inhibiting new blood vessel formation, the antibody is expected to have activity against a wide variety of solid tumors that rely on angiogenesis to grow and metastasize. CD105 is also expressed on cancer stem cells.

TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent in combination with temozolomide (Temodar(R)).

"TRACON remains on schedule to deliver three Phase 2-ready assets in 2009 including two monoclonal antibodies," commented Charles P. Theuer MD PhD, President and CEO of TRACON Pharmaceuticals. "We are currently engaged in manufacturing and clinical development activities to support comprehensive Phase 2 programs."

The presentation details are as follows:

    Abstract Title: Phase 1 study of TRC105 (anti-CD105 (endoglin) antibody)
    therapy in patients with advanced refractory cancer
    Presenter: Lee Rosen, MD, Premiere Oncology - Los Angeles
    Date and Time: Friday, May 29, 2009, 2:00 PM - 6:00 PM
    Session Title: Developmental Therapeutics
    Session Type: Poster Discussion
    Abstract Number: 3518

    Abstract Title: A Phase 1 study of daily oral TRC102 (methoxyamine) to
    enhance the therapeutic effects of pemetrexed in patients with advanced
    refractory cancer
    Presenter: Steven Anthony, DO, Evergreen Hematology and Oncology
    Date and Time: Saturday, May 30, 2009, 8:00 AM - 12:00 PM
    Session Title: Developmental Therapeutics
    Session Type: Poster Presentation
    Abstract Number: 2552


TRACON Pharmaceuticals is a privately held biotechnology company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis and tumor growth that began dosing in a Phase 1 clinical trial in cancer patients in July, 2007. TRC105 is a monoclonal antibody that binds CD105 (endoglin) to inhibit angiogenesis that began dosing in a Phase 1 clinical trial in cancer patients in January, 2008. TRC102, a small molecule that reverses resistance to chemotherapeutics, began dosing in 2008 in a Phase 1 trial in combination with Temodar(R) and a Phase 1 trial in combination with Alimta(R). Further information about TRACON Pharmaceuticals can be found at

    Alison Fishman, TRACON Pharmaceuticals, Inc.

SOURCE TRACON Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
2. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
3. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
4. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
5. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
6. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
7. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
10. Transcept Pharmaceuticals to Report First Quarter 2009 Results
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... ... exchange technology and teleradiology services, has added Chris Hafey and Claude Hooton to ... at the Radiological Society of North America (RSNA) 2015 Annual Meeting and continues ...
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... Denver, CO (PRWEB) , ... November 27, 2015 , ... ... U.S. cities are not changing the way that they are handling security in light ... increasing police and security presence in an attempt to stop an attack from reaching ...
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
Breaking Medicine News(10 mins):